Session » (2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 2394

18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry

9:00AM-11:00AM: Abstract Number: 2402

A Retrospective Analysis of Prevalence of Positive Temporal Artery Biopsies in African American Patients with Giant Cell Arteritis (GCA) in a Large Academic Health Center

9:00AM-11:00AM: Abstract Number: 2401

A Study Defining the Optimal Sonographic Parameters for Intima-Media Thickness in Diagnosing Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2400

Applanation Tonometry of the Temporal Arteries in Participants with Suspected Giant Cell Arteritis: A Proof of Concept

9:00AM-11:00AM: Abstract Number: 2411

C-X-C Motif Chemokine Receptor 4-targeted Molecular Imaging in Giant Cell Arteritis – a Head-to-head Comparison with FDG PET

9:00AM-11:00AM: Abstract Number: 2389

Calprotectin (S100A8/S100A9) and Serumamyloid A Are Not Superior to C Reactive Protein and Erythrocyte Sedimentation Rate in Monitoring Disease Activity in Giant Cell Arteritis – Treated with or Without Tocilizumab

9:00AM-11:00AM: Abstract Number: 2392

Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2390

Characterization of Senescent Cells in Temporal Arteries of Patients with Giant Cell Arteritis Reveal an Inflammatory Phenotype and Strong Dependence from IL-6

9:00AM-11:00AM: Abstract Number: 2416

Comparison of Clinical, Laboratory and Imaging Features of Relapses Between Takayasu and LV-GCA Patients. an Italian Monocentric Study

9:00AM-11:00AM: Abstract Number: 2423

Concordance Between the 1990 ACR Classification Criteria and the New 2022 ACR/EULAR 2022 Criteria in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2409

Concordance of Relapse Symptoms with Initial Baseline Presentation Features Among Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2393

CXCL9/IL-6 and MMP3/CD141 Ratio Allow to Discriminate Between Isolated PMR and GCA/PMR Overlap

9:00AM-11:00AM: Abstract Number: 2396

Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2418

Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment

9:00AM-11:00AM: Abstract Number: 2391

Epidemiology and Predictors of Relapse in Giant Cell Arteritis: Results of the ARTESER Register

9:00AM-11:00AM: Abstract Number: 2412

Evaluation of the Pretest Probability Score, Ultrasound and Biopsy on GCA Diagnose: Data from Real Clinical Practice

9:00AM-11:00AM: Abstract Number: 2424

Exploring the Limit of Image Resolution for Human Expert Classification of Vascular Ultrasound Images in Giant Cell Arteritis and Healthy Subjects: The GCA-US-AI Project

9:00AM-11:00AM: Abstract Number: 2398

FDG Uptake in Limb Arteries at Diagnosis of Giant Cell Arteritis and Risk of Relapse: An Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 2415

Giant Cell Arteritis Is Associated with Worse Hospital Outcomes in Aortic Aneurysm/Dissection Hospitalizations: A Nationwide United States Population-Based Study

9:00AM-11:00AM: Abstract Number: 2407

Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2397

Impact of Exposure to Environmental Air Pollution on the Onset of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2388

Increased Risk of Severe Infections in Early Giant Cell Arteritis: A Population- based Study

9:00AM-11:00AM: Abstract Number: 2417

Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study

9:00AM-11:00AM: Abstract Number: 2413

Janus Kinase Inhibitors in Giant Cell Arteritis in Clinical Practice. Real-World Clinical Practice Study and Literature Review

9:00AM-11:00AM: Abstract Number: 2387

Large Vessel Involvement and the Risk of Severe Infections in Patients with Giant Cell Arteritis – a Population-based Study

9:00AM-11:00AM: Abstract Number: 2422

Magnetic Resonance Imaging Reflects Disease Activity in the “Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab” Trial (The GUSTO Trial)

9:00AM-11:00AM: Abstract Number: 2421

Optic Nerve Sheath Measurement on Ultrasound: A Novel Diagnostic Test for Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2395

Recommendations for Early Referral of Patients with Suspected Polymyalgia Rheumatica: An Initiative from the International Giant Cell Arteritis and Polymyalgia Rheumatica Study Group

9:00AM-11:00AM: Abstract Number: 2414

Relapse in Giant Cell Arteritis Treated with Tocilizumab. Predictive Factors

9:00AM-11:00AM: Abstract Number: 2406

Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study

9:00AM-11:00AM: Abstract Number: 2405

Role of Mitochondria in Activation of Platelets in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2420

Sex Differences in Giant Cell Arteritis: Data from the ARTESER Registry

9:00AM-11:00AM: Abstract Number: 2404

Subclinical Giant Cell Arteritis in Polimialgia Rheumatica: A Biomarker of High Relapse Risk

9:00AM-11:00AM: Abstract Number: 2403

Systole and Diastole Ultrasound Wall Thickness Shows Significant Differences That Affect the Diagnosis and Assessment of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2408

The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts

9:00AM-11:00AM: Abstract Number: 2410

Tocilizumab versus Methotrexate in Giant Cell Arteritis: A Retrospective Study to Compare Efficacy and Rapidity of These Steroid-sparing Agents in GCA Patients

9:00AM-11:00AM: Abstract Number: 2399

Ultrasound Is Comparable to Computed Tomography Angiography in Identifying Aortic Aneurysms in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2419

Visual Manifestations in Giant Cell Arteritis: Identification of Risk Factors from the ARTESER Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].